A comparison between neurally	1
A comparison	1
bone marrow derived mesenchymal stem cells and olfactory ensheathing glial cells to repair spinal cord injuries in rat Saeed Oraee Yazdania , b , c , Mirsepehr Pedramd , Maryam Hafizib , Mahboubeh Kabirib , f , Masoud Soleimanie , ∗ , Mohamad-Mehdi Dehghand , Issa Jahanzadg , Yousof Gheisarib , Seyed Mahmoud Hashemib , h a b s t r a c t Cell therapy has proven to be a highly promising method in clinical applications	39
bone marrow	39
mesenchymal stem cells and olfactory ensheathing glial cells	59
mesenchymal stem cells	59
olfactory ensheathing glial cells	86
spinal cord injuries in rat	130
spinal cord injuries	130
rat	154
Saeed	159
Oraee Yazdania , b , c , Mirsepehr Pedramd , Maryam Hafizib , Mahboubeh Kabirib , f , Masoud Soleimanie , ∗ , Mohamad-Mehdi Dehghand , Issa Jahanzadg , Yousof Gheisarib , Seyed Mahmoud Hashemib , h	165
Oraee Yazdania	165
b	180
c	182
Mirsepehr Pedramd	185
Maryam Hafizib	204
Mahboubeh Kabirib	220
f	238
Masoud Soleimanie	241
∗	259
Mohamad-Mehdi Dehghand	262
Issa Jahanzadg	286
Yousof Gheisarib	302
Seyed Mahmoud Hashemib	320
h	343
a b	346
t r	352
a c t Cell therapy	356
a highly promising method in clinical applications	392
a highly promising method	392
clinical applications	421
so much hope for the treatment of injured tissues	452
so much hope	452
the treatment of injured tissues	469
the treatment	469
injured tissues	486
low , if any , self regeneration potential such as central and peripheral nervous system	507
low , if any , self	507
regeneration potential such as central and peripheral nervous system	525
regeneration potential	525
central and peripheral nervous system	556
central	556
peripheral nervous system	568
bone marrow derived mesenchymal stem cells -LRB- NIMSCs -RRB- as well as olfactory ensheathing cells -LRB- OECs -RRB- were transplanted in a rat model of sub-acute spinal cord injury	612
bone marrow derived mesenchymal stem cells -LRB- NIMSCs -RRB-	612
bone marrow derived mesenchymal stem cells	612
bone marrow	612
mesenchymal stem cells	632
NIMSCs	656
olfactory ensheathing cells -LRB- OECs -RRB- were transplanted in a rat model of sub-acute spinal cord injury	675
olfactory ensheathing cells	675
OECs	704
a rat model of sub-acute spinal cord injury	731
a rat model	731
sub-acute spinal cord injury	746
the behavioral and histological analyses	779
A balloon-compression technique	836
an injury at T8 -- T9 level of spinal cord	888
an injury at T8	888
an injury	888
T8	901
T9 level of spinal cord	904
T9 level	904
spinal cord	916
a week post injury	935
rats	955
either NIMSCs or OECs	979
the center of developing lesion cavity , 3 mm cranial and 3 mm caudal to the cavity	1004
the center	1004
lesion cavity , 3 mm cranial and 3 mm caudal	1029
lesion cavity	1029
3 mm cranial	1044
3 mm caudal	1061
the cavity	1076
Weekly behavioral assessment using BBB score	1088
Weekly behavioral assessment	1088
BBB score	1123
five-week period post transplantation	1147
histological assessment	1197
labeled cells	1245
the tissue	1262
the reduction of cavity formation and axonal regeneration	1294
the reduction	1294
cavity formation and axonal regeneration	1311
cavity formation	1311
axonal regeneration	1332
Evaluation of locomotor performance	1353
Evaluation	1353
locomotor performance	1367
significant behavioral improvement	1396
NIMSC group	1434
OEC and control groups	1451
The histological analyses	1475
the presence of transplanted cells in the spinal cord parenchyma	1510
the presence	1510
transplanted cells in the spinal cord parenchyma	1526
transplanted cells	1526
the spinal cord parenchyma	1548
Volume of injured area that was occupied with syrinx cavity in NIMSC group	1576
Volume	1576
injured area that was occupied with syrinx cavity in NIMSC group	1586
injured area	1586
syrinx cavity in NIMSC group	1622
syrinx cavity	1622
NIMSC group	1639
control group	1679
addition	1697
neurofilament-positive axons	1717
higher expression	1767
rats receiving NIMSC compared to the other two groups	1788
rats	1788
NIMSC	1803
the other two groups	1821
conclusion NIMSC	1846
both behavioral and histological improvement that potentially makes them	1870
them	1938
a promising candidate for cell therapy approaches of spinal cord injuries	1943
a promising candidate	1943
cell therapy approaches of spinal cord injuries	1969
cell therapy approaches	1969
spinal cord injuries	1996
Introduction Spinal cord injury -LRB- SCI -RRB-	2022
Introduction Spinal cord injury	2022
Introduction	2022
Spinal cord injury	2035
SCI	2055
a debilitating disorder imposing high social , psychological and financial burden on patients , families and governments	2063
a debilitating disorder	2063
high social , psychological and financial burden on patients , families and governments	2096
high social , psychological and financial burden	2096
patients , families and governments	2147
This disorder	2183
paraplegia or quadriplegia	2211
the trauma site	2251
sensation	2279
Most of these patients	2290
Most	2290
these patients	2298
difficulty in controlling urination and defecation	2318
difficulty	2318
urination and defecation	2344
The importance of regenerative medicine	2370
The importance	2370
regenerative medicine	2388
peripheral nervous system -LRB- PNS -RRB-	2461
peripheral nervous system	2461
PNS	2488
the central nervous system -LRB- CNS -RRB-	2494
the central nervous system	2494
CNS	2522
no capacity for regeneration , which in turn can be due to inhibitory factors produced and released in the damaged area -LRB- Filbin , 2003 -RRB-	2531
no capacity	2531
regeneration , which in turn can be due to inhibitory factors produced and released in the damaged area -LRB- Filbin , 2003 -RRB-	2547
regeneration	2547
turn	2570
inhibitory factors produced and released in the damaged area -LRB- Filbin , 2003 -RRB-	2589
inhibitory factors	2589
the damaged area -LRB- Filbin , 2003 -RRB-	2633
the damaged area	2633
Filbin , 2003	2651
Filbin	2651
2003	2659
addition	2669
secondary neurodegeneration	2679
place	2713
the surrounding tissue site due to inflammatory factors	2722
the surrounding tissue site	2722
inflammatory factors	2757
substantially the prognosis -LRB- Andrade et al. , 2008 -RRB-	2791
substantially the prognosis	2791
Andrade	2820
et al. , 2008	2828
et al.	2828
2008	2836
High dose corticosteroid injection within 48 h after damage	2843
High dose corticosteroid injection	2843
48 h after damage	2885
48 h	2885
damage	2896
the only accepted clinical method	2906
consequences of spinal damages -LRB- Bracken , 2001 -RRB-	2950
consequences	2950
spinal damages -LRB- Bracken , 2001 -RRB-	2966
spinal damages	2966
Bracken	2982
2001	2991
Cell therapy	2998
an issue that has raised much hope in regeneration of CNS and PNS	3014
an issue	3014
much hope	3039
regeneration of CNS and PNS	3052
regeneration	3052
CNS and PNS	3068
various cell types	3090
CNS	3138
Stem cells with the capacity of self renewal and differentiation to different cell types	3143
Stem cells	3143
the capacity of self renewal and differentiation to different cell types	3159
the capacity	3159
self renewal and differentiation	3175
different cell types	3211
key cells for neural regeneration -LRB- Kim and de Vellis , 2009 ; Rossi and Keirstead , 2009 -RRB-	3250
key cells	3250
neural regeneration -LRB- Kim and de Vellis , 2009 ; Rossi and Keirstead , 2009 -RRB-	3264
neural regeneration	3264
Kim and de Vellis , 2009 ; Rossi and Keirstead , 2009	3285
Kim and de Vellis	3285
Kim	3285
de Vellis	3293
Vellis	3296
2009 ; Rossi	3304
2009	3304
Rossi	3310
Keirstead , 2009	3320
Keirstead	3320
2009	3331
Neural stem cells -LRB- Einstein and Ben-Hur , 2008 -RRB- , embryonic stem cells -LRB- McDonald et al. , 2004 -RRB- , mesenchymal stem cells -LRB- MSCs -RRB- -LRB- Vaquero and Zurita , 2009 -RRB- and pluripotent hair follicle stem cells -LRB- Liu et al. , 2011 -RRB-	3338
Neural stem cells -LRB- Einstein and Ben-Hur , 2008 -RRB- , embryonic stem cells -LRB- McDonald et al. , 2004 -RRB- , mesenchymal stem cells -LRB- MSCs -RRB- -LRB- Vaquero and Zurita , 2009 -RRB- and pluripotent hair follicle stem cells	3338
Neural stem cells -LRB- Einstein and Ben-Hur , 2008 -RRB-	3338
Neural stem cells	3338
Einstein and Ben-Hur	3357
2008	3379
embryonic stem cells -LRB- McDonald et al. , 2004 -RRB-	3386
embryonic stem cells	3386
McDonald	3408
et al. , 2004	3417
et al.	3417
2004	3425
mesenchymal stem cells -LRB- MSCs -RRB- -LRB- Vaquero and Zurita , 2009 -RRB-	3432
mesenchymal stem cells -LRB- MSCs -RRB-	3432
mesenchymal stem cells	3432
MSCs	3456
Vaquero and Zurita	3463
2009	3483
pluripotent hair follicle stem cells	3493
Liu	3531
et al. , 2011	3535
et al.	3535
2011	3543
CNS	3573
different levels of success	3582
different levels	3582
success	3602
recent years	3614
MSCs	3628
the spotlight of cell therapy	3646
the spotlight	3646
cell therapy	3663
various remarkable properties	3687
they	3717
lack of immunologic rejection	3736
lack	3736
immunologic rejection	3744
strong secretory properties and their plasticity	3774
strong secretory properties	3774
their plasticity	3806
different cell types -LRB- Caplan , 2007 -RRB-	3839
different cell types	3839
Caplan	3861
2007	3869
stem cells	3884
more recently lineage committed stem cells	3896
lineage	3910
CNS regeneration -LRB- Lu et al. , 2006 ; Marques et al. , 2010 ; Ye et al. , 2007 -RRB-	3963
CNS regeneration	3963
Lu et al. , 2006 ; Marques et al. , 2010 ; Ye et al. , 2007	3981
Lu	3981
et al. , 2006 ; Marques et al. , 2010 ; Ye et al. , 2007	3984
et al. , 2006	3984
et al.	3984
2006	3992
Marques et al. , 2010	3998
Marques	3998
et al. , 2010	4006
et al.	4006
2010	4014
Ye et al. , 2007	4020
Ye	4020
et al. , 2007	4023
et al.	4023
2007	4031
our previous study	4041
we	4061
transplantation of neurally induced MSC into the sub-acute model of SCI	4076
transplantation	4076
MSC	4112
the sub-acute model of SCI	4121
the sub-acute model	4121
SCI	4144
significant behavioral improvement	4155
undifferentiated MSC -LRB- Pedram et al. , 2009 -RRB-	4207
undifferentiated MSC	4207
Pedram	4229
et al. , 2009	4236
et al.	4236
2009	4244
Glial cells such as schwann cells and olfactory ensheathing cells -LRB- OECs -RRB-	4251
Glial cells such as schwann cells and olfactory ensheathing cells	4251
Glial cells	4251
schwann cells and olfactory ensheathing cells	4271
schwann cells	4271
olfactory ensheathing cells	4289
OECs	4318
spinal cord regeneration	4351
some other studies showing their positive effect in CNS regeneration -LRB- García-Alías et al. , 2004 ; Kocsis et al. , 2009 ; Ramer et al. , 2004 -RRB-	4381
some other studies	4381
their positive effect	4408
CNS regeneration -LRB- García-Alías et al. , 2004 ; Kocsis et al. , 2009 ; Ramer et al. , 2004 -RRB-	4433
CNS regeneration	4433
García-Alías et al. , 2004 ; Kocsis et al. , 2009 ; Ramer et al. , 2004	4451
García-Alías	4451
et al. , 2004 ; Kocsis et al. , 2009 ; Ramer et al. , 2004	4464
et al. , 2004	4464
et al.	4464
2004	4472
Kocsis et al. , 2009	4478
Kocsis	4478
et al. , 2009	4485
et al.	4485
2009	4493
Ramer et al. , 2004	4499
Ramer	4499
et al. , 2004	4505
et al.	4505
2004	4513
OECs	4520
unique glial cells found in the olfactory systems that support olfactory neurogenesis and the retargeting across the PNS/CNS boundary in the olfactory system	4529
unique glial cells	4529
the olfactory systems that support olfactory neurogenesis and the retargeting across the PNS/CNS boundary in the olfactory system	4557
the olfactory systems	4557
olfactory neurogenesis and the retargeting	4592
olfactory neurogenesis	4592
the retargeting	4619
the PNS/CNS boundary in the olfactory system	4642
the PNS/CNS boundary	4642
the olfactory system	4666
These cells	4688
tissue sparing and neuroprotection	4722
outgrowth of both intact and lesioned axons	4766
outgrowth	4766
both intact and lesioned axons	4779
angiogenesis and remyelinate axons	4820
a range of demyelinating insults -LRB- Richter and Roskams , 2008 -RRB-	4861
a range	4861
demyelinating insults -LRB- Richter and Roskams , 2008 -RRB-	4872
demyelinating insults	4872
Richter and Roskams	4895
2008	4916
this study	4926
we	4938
transplantation of NIMSC and OECs	4950
transplantation	4950
NIMSC and OECs	4969
a sub-acute model of SCI	4987
a sub-acute model	4987
SCI	5008
rats	5015
the regeneration of neural tissue	5041
the regeneration	5041
neural tissue	5061
the damaged area	5078
Material and methods 2.1 .	5100
Material and methods	5100
2.1	5121
Isolation and culture of primary rat OECs Highly purified cultures of OEC	5126
Isolation and culture	5126
primary rat OECs Highly purified cultures of OEC	5151
primary rat OECs	5151
cultures of OEC	5184
cultures	5184
OEC	5196
the nerve fiber layer of the olfactory bulb of neonatal rats	5219
the nerve fiber layer	5219
the olfactory bulb of neonatal rats	5244
the olfactory bulb	5244
neonatal rats	5266
a procedure first described by Ramon-Cueto et al. -LRB- 1998 -RRB- and later modified by Pearse et al. -LRB- 2007 -RRB-	5286
a procedure	5286
Ramon-Cueto	5317
et al. -LRB- 1998 -RRB-	5329
et al.	5329
1998	5337
Pearse	5365
et al. -LRB- 2007 -RRB-	5372
et al.	5372
2007	5380
the pia	5396
so much care	5421
the inclusion of any bulb nerve fiber	5446
the inclusion	5446
any bulb nerve fiber	5463
Tissue	5485
trypsin and collagenase -LRB- both from Gibcoo , USA -RRB- and the dissociated cells were exposed to forskolin -LRB- 0.8 g/mL , Sigma , USA -RRB- and pituitary extract -LRB- 2 mg/mL -RRB- in DMEM/F12/10 % FBS -LRB- Sigma , USA -RRB- for 5 days	5525
trypsin and collagenase -LRB- both from Gibcoo , USA -RRB-	5525
trypsin and collagenase	5525
both from Gibcoo , USA	5550
both	5550
Gibcoo , USA	5560
the dissociated cells were exposed to forskolin -LRB- 0.8 g/mL , Sigma , USA -RRB- and pituitary extract -LRB- 2 mg/mL -RRB- in DMEM/F12/10 % FBS -LRB- Sigma , USA -RRB- for 5 days	5577
the	5577
cells	5593
forskolin -LRB- 0.8 g/mL , Sigma , USA -RRB- and pituitary extract -LRB- 2 mg/mL -RRB-	5615
forskolin	5615
0.8 g/mL	5626
Sigma	5637
USA	5644
pituitary extract	5653
2 mg/mL	5672
DMEM/F12/10 % FBS -LRB- Sigma , USA -RRB- for 5 days	5684
DMEM/F12/10 % FBS -LRB- Sigma , USA -RRB-	5684
DMEM/F12/10 % FBS	5684
Sigma	5702
USA	5709
5 days	5718
final purification by p75 immunopanning as previously described -LRB- Takami et al. , 2002 -RRB-	5733
final purification	5733
p75 immunopanning as previously described -LRB- Takami et al. , 2002 -RRB-	5755
p75 immunopanning	5755
Takami	5798
et al. , 2002	5805
et al.	5805
2002	5813
Cells	5820
confluence	5840
passage 3	5864
The purity of the cells	5875
The purity	5875
the cells	5889
p75 antibody -LRB- Rabbit polyclonal , Abcam , USA -RRB-	5919
p75 antibody	5919
Rabbit polyclonal , Abcam , USA	5933
Rabbit polyclonal	5933
Abcam	5952
USA	5959
the OECs	5989
transplantation	6004
cells	6021
72 h with bromodeoxyuridine -LRB- BrdU , 10 g/mL , Sigma , USA -RRB- , before engraftment -LRB- Gratzner , 1982 -RRB-	6047
72 h with bromodeoxyuridine -LRB- BrdU , 10 g/mL , Sigma , USA -RRB- , before engraftment	6047
72 h with bromodeoxyuridine	6047
72 h	6047
bromodeoxyuridine	6057
BrdU	6076
10 g/mL	6082
Sigma , USA	6092
engraftment	6112
Gratzner , 1982	6125
Gratzner	6125
1982	6135
Unincorporated BrdU , which is a thymidine analog and marker of newly synthesized DNA ,	6142
Unincorporated BrdU	6142
a thymidine analog and marker of newly synthesized DNA	6172
a thymidine analog and marker	6172
newly synthesized DNA	6205
extensive washing before transplantation	6244
extensive	6244
transplantation	6269
2.2	6286
Isolation and culture of primary rat MSCs MSCs	6291
Isolation and culture	6291
primary rat MSCs MSCs	6316
adult female wistar rat -LRB- weight = 90 -- 100 g -RRB-	6357
adult female wistar rat	6357
weight	6382
= 90 -- 100 g	6389
= 90	6389
100 g	6394
a modified procedure described previously -LRB- Hofstetter et al. , 2002 -RRB-	6407
a modified procedure described previously	6407
a modified procedure	6407
Hofstetter	6450
et al. , 2002	6461
et al.	6461
2002	6469
brief	6479
anesthetization and euthanization of rats	6492
anesthetization and euthanization	6492
rats	6529
femures and tibias	6535
distal epiphyses	6585
An 18-guage needle	6616
the proximal end of the bone	6653
the proximal end	6653
the bone	6673
marrow	6686
sterile cryovials	6710
ice	6742
The whole bone marrow suspension	6747
T25 flasks	6796
The cells	6808
DMEM/F12	6840
10 % FBS and 1 % penicillin/streptomycin	6860
10 % FBS	6860
1 % penicillin/streptomycin	6872
3 days	6906
cells	6930
the fresh medium in new flasks	6972
the fresh medium	6972
new flasks	6992
Cells	7004
confluence	7024
passage 3	7047
cell surface antigen characterization	7062
MSC antigens	7101
flowcytometry using fluorescein isothio-cyanate-conjugated -LRB- FITC -RRB- mouse anti-rat CD31 -LRB- AbD Serotec , UK -RRB- and CD44 -LRB- Cedarlane , Canada -RRB- , phycoerythrin-conjugated -LRB- PE -RRB- mouse anti-rat CD45 -LRB- BioLegend , USA -RRB- , CD90 -LRB- eBioscience , USA -RRB- and CD73 -LRB- BD Biosciences , USA -RRB-	7131
flowcytometry using fluorescein	7131
flowcytometry	7131
fluorescein	7151
isothio-cyanate-conjugated -LRB- FITC -RRB- mouse	7163
FITC	7191
anti-rat CD31 -LRB- AbD Serotec , UK -RRB-	7203
anti-rat CD31	7203
AbD Serotec	7218
UK	7231
CD44 -LRB- Cedarlane , Canada -RRB- , phycoerythrin-conjugated -LRB- PE -RRB- mouse anti-rat CD45 -LRB- BioLegend , USA -RRB- , CD90 -LRB- eBioscience , USA -RRB- and CD73 -LRB- BD Biosciences , USA -RRB-	7239
CD44 -LRB- Cedarlane , Canada -RRB-	7239
CD44	7239
Cedarlane	7245
Canada	7256
phycoerythrin-conjugated -LRB- PE -RRB- mouse anti-rat CD45 -LRB- BioLegend , USA -RRB-	7265
phycoerythrin-conjugated -LRB- PE -RRB- mouse anti-rat CD45	7265
phycoerythrin-conjugated -LRB- PE -RRB- mouse	7265
PE	7291
anti-rat CD45	7301
BioLegend	7316
USA	7327
CD90 -LRB- eBioscience , USA -RRB-	7333
CD90	7333
eBioscience	7339
USA	7352
CD73 -LRB- BD Biosciences , USA -RRB-	7361
CD73	7361
BD Biosciences	7367
USA	7383
Multilineage differentiation potential	7389
the ability of bone marrow derived MSCs to differentiate into adipocytes and osteoblasts , as previously described -LRB- Pittenger et al. , 1999 -RRB-	7452
the ability	7452
bone marrow derived MSCs to differentiate into adipocytes and osteoblasts , as previously described	7467
bone marrow	7467
MSCs	7487
adipocytes and osteoblasts	7514
Pittenger	7567
et al. , 1999	7577
et al.	7577
1999	7585
Oil red O and alizarin red staining	7592
Oil red O	7592
alizarin red staining	7606
adipocytes and osteoblasts	7653
A recombinant adenovirus carrying the green fluorescent protein -LRB- GFP -RRB- gene	7695
A recombinant adenovirus	7695
the green fluorescent protein -LRB- GFP -RRB- gene	7729
GFP	7760
MSCs transduction as described previously -LRB- Satake et al. , 2004 -RRB-	7783
MSCs transduction	7783
Satake	7826
et al. , 2004	7833
et al.	7833
2004	7841
that , at the time of transduction , defined as day 1 , 2 mL of virus solution and 2 mL of complete medium	7854
that	7854
the time of transduction	7863
the time	7863
transduction	7875
day 1 , 2 mL of virus solution and 2 mL of complete medium	7900
day 1	7900
2 mL of virus solution	7907
2 mL	7907
virus solution	7915
2 mL of complete medium	7934
2 mL	7934
complete medium	7942
final 108 plaque	7959
unit -LRB- PFU -RRB-	7984
unit	7984
PFU	7990
106 cells	8016
24 h incubation at 37 ◦ C	8033
24 h incubation	8033
37 ◦ C	8052
virus solution	8059
complete fresh medium	8090
2 -- 3 days post transduction	8119
2	8119
3 days post transduction	8121
3 days	8121
post transduction	8128
MSCs	8147
0.3 % collagenase/DMEM	8172
1 min followed by 0.05 % trypsin/0 .03 % EDTA for 5 min	8198
1 min	8198
0.05 % trypsin/0 .03 % EDTA for 5 min	8216
0.05 % trypsin/0 .03 % EDTA	8216
0.05 % trypsin/0 .03 %	8216
0.05 %	8216
trypsin/0 .03 %	8222
5 min	8245
Fluorescent microscopy	8252
cells	8299
transplantation	8336
2.3	8353
Neural differentiation of MSCs MSCs	8358
Neural differentiation	8358
MSCs MSCs	8384
neurons using a modified procedure described previously in details -LRB- Deng et al. , 2001 -RRB-	8410
neurons	8410
a modified procedure described previously in details -LRB- Deng et al. , 2001 -RRB-	8424
a modified procedure	8424
details -LRB- Deng et al. , 2001 -RRB-	8469
details	8469
Deng	8478
et al. , 2001	8483
et al.	8483
2001	8491
brief	8501
the cells	8508
DMEM/F12 containing 0.5 mM 3-isobutyl - 1-methylxanthine -LRB- IBMX , Sigma , USA -RRB- and 1 mM retinoid acid -LRB- RA , Sigma , USA -RRB- for 7 days	8535
DMEM/F12	8535
0.5 mM 3-isobutyl - 1-methylxanthine -LRB- IBMX , Sigma , USA -RRB- and 1 mM retinoid acid -LRB- RA , Sigma , USA -RRB- for 7 days	8555
0.5 mM 3-isobutyl - 1-methylxanthine -LRB- IBMX , Sigma , USA -RRB-	8555
0.5 mM 3-isobutyl	8555
1-methylxanthine -LRB- IBMX , Sigma , USA -RRB-	8574
1-methylxanthine	8574
IBMX	8592
Sigma	8598
USA	8605
1 mM retinoid acid -LRB- RA , Sigma , USA -RRB- for 7 days	8614
1 mM retinoid acid -LRB- RA , Sigma , USA -RRB-	8614
1 mM retinoid acid	8614
RA	8634
Sigma	8638
USA	8645
7 days	8654
All culture media	8662
every 2 -- 3 days	8693
every 2	8693
3 days	8701
7 days of induction	8715
7 days	8715
induction	8725
cells	8736
engraftment	8757
transplantation	8777
the cells	8794
any changes in morphology and production of neural specific proteins	8822
any changes	8822
morphology and production of neural specific proteins	8837
morphology and production	8837
neural specific proteins	8866
the induced cells	8902
4 % paraformaldehyde for 20 min , permeabilized with Triton X-100 -LRB- 0.2 % -RRB-	8936
4 % paraformaldehyde	8936
20 min , permeabilized with Triton X-100 -LRB- 0.2 % -RRB-	8960
20 min	8960
permeabilized with Triton X-100 -LRB- 0.2 % -RRB-	8968
permeabilized with Triton X-100	8968
Triton	8987
0.2 %	9001
immunocytochemistry using mouse monoclonal anti-beta-tubulin III -LRB- 1:50 , Abcam , USA -RRB- , mouse monoclonal anti-myelin associated protein 2 -LRB- MAP2 , 1:50 , Abcam , USA -RRB- and FITC-conjugated anti-mouse secondary antibody -LRB- 1:500 , Sigma , USA -RRB-	9020
immunocytochemistry using mouse monoclonal anti-beta-tubulin III -LRB- 1:50 , Abcam , USA -RRB-	9020
immunocytochemistry	9020
mouse monoclonal anti-beta-tubulin III -LRB- 1:50 , Abcam , USA -RRB-	9046
mouse monoclonal	9046
III	9081
1:50	9086
Abcam	9092
USA	9099
mouse monoclonal anti-myelin associated protein 2 -LRB- MAP2 , 1:50 , Abcam , USA -RRB-	9105
mouse monoclonal anti-myelin	9105
protein 2 -LRB- MAP2 , 1:50 , Abcam , USA -RRB-	9145
protein 2	9145
MAP2	9156
1:50	9162
Abcam , USA	9168
FITC-conjugated anti-mouse secondary antibody -LRB- 1:500 , Sigma , USA -RRB-	9184
FITC-conjugated anti-mouse secondary antibody	9184
1:500	9231
Sigma	9238
USA	9245
2.4	9251
Induction of spinal cord injury Adult female wistar rats -LRB- n = 21 , weight 300 -- 350 g -RRB-	9256
Induction	9256
spinal cord injury Adult female wistar rats -LRB- n = 21 , weight 300 -- 350 g -RRB-	9269
spinal cord injury Adult female wistar rats	9269
n	9314
= 21 , weight 300 -- 350 g	9316
= 21	9316
weight 300	9322
350 g	9333
spinal contusion injury using Fogarty catheter as detailed previously -LRB- Vanicky ' et al. , 2001	9349
spinal contusion injury	9349
Fogarty catheter	9379
previously -LRB- Vanicky ' et al. , 2001	9408
previously -LRB- Vanicky ' et al.	9408
previously	9408
Vanicky ' et al.	9420
Vanicky '	9420
et al.	9429
2001	9437
laminotomy	9453
T10 vertebral level in anesthetized rats	9476
T10 vertebral level	9476
anesthetized rats	9499
dental drill	9523
A two French Fogarty catheter was filled with saline and connected to an air tight 50 µl hamilton syringe , held in a precise sampling device .	9537
A two French Fogarty catheter	9537
two	9539
saline	9583
an air	9607
tight 50 µl hamilton syringe	9614
tight 50 µl	9614
50	9620
hamilton syringe	9626
a precise sampling device	9652
The catheter	9679
the epidural space	9710
1 cm	9756
the center of the balloon	9770
the center	9770
the balloon	9784
T8	9806
T9 level of the spinal cord	9809
T9 level	9809
the spinal cord	9821
The balloon	9838
a defined volume of saline -LRB- 15 µl -RRB- for 5 min	9881
a defined volume	9881
saline -LRB- 15 µl -RRB- for 5 min	9901
saline -LRB- 15 µl -RRB-	9901
saline	9901
15 µl	9909
5 min	9920
that	9933
catheter	9939
muscles and skin	9979
layers	10011
surgery	10025
rats	10034
large cages	10058
Manual bladder expression	10071
reflex bladder	10138
Antibiotic therapy with enrofloxacin -LRB- 10 mg/kg , every 24 h -RRB-	10170
Antibiotic therapy with enrofloxacin	10170
Antibiotic therapy	10170
enrofloxacin	10194
10 mg/kg , every 24 h	10208
10 mg/kg	10208
every 24 h	10218
one	10250
week	10254
All experiments	10260
the guidelines of the Iran Animal Care Committee	10285
the guidelines	10285
the Iran Animal Care Committee	10303
the faculty of veterinary medicine animal care committee	10355
the faculty	10355
veterinary medicine animal care committee	10370
2.5	10413
Transplantation Prior to implantation , GFP-transduced NIMSCs and BrdU positive OECs	10418
implantation , GFP-transduced NIMSCs and BrdU	10443
implantation	10443
GFP-transduced NIMSCs	10457
BrdU	10483
culture via trypsinization	10522
culture	10522
trypsinization	10534
cells	10555
fresh DMEM/F12	10594
Appropriate aliquots of cells	10622
Appropriate aliquots	10622
cells	10646
ice	10665
surgery	10678
One week	10687
SCI	10702
the rats	10707
a small hole	10738
the vertebral arches of T8 and/or T9	10763
the vertebral arches	10763
T8 and/or T9	10787
T8	10787
T9	10797
a micromotor	10806
The tip of a 20 µl hamilton syringe connected to a microinjector	10820
The tip	10820
a 20 µl hamilton syringe	10831
a microinjector	10869
the intact dura	10906
the center of the developing lesion cavity , 3 mm cranial and 3 mm caudal to the cavity -LRB- penetration depth of 1.0 mm at an angle of 40 -- 45 ◦ past perpendicular -RRB-	10927
the center	10927
the developing lesion cavity , 3 mm cranial and 3 mm caudal to the cavity -LRB- penetration depth of 1.0 mm at an angle of 40 -- 45 ◦ past perpendicular -RRB-	10941
the developing lesion cavity	10941
3 mm cranial	10971
3 mm caudal to the cavity -LRB- penetration depth of 1.0 mm at an angle of 40 -- 45 ◦ past perpendicular -RRB-	10988
3 mm caudal	10988
the cavity -LRB- penetration depth of 1.0 mm at an angle of 40 -- 45 ◦ past perpendicular -RRB-	11003
the cavity	11003
penetration depth of 1.0 mm at an angle of 40 -- 45 ◦ past perpendicular	11015
penetration depth	11015
1.0 mm at an angle of 40 -- 45 ◦ past perpendicular	11036
1.0 mm	11036
an angle of 40 -- 45 ◦ past perpendicular	11046
an angle	11046
40 -- 45 ◦ past perpendicular	11058
40 -- 45	11058
The rate of injection	11086
The rate	11086
injection	11098
2 µl/min	11112
The hamilton syringe	11122
place for an additional 1 min	11155
place	11155
an additional 1 min	11165
leakage	11197
withdrawal	11210
Rats	11222
3 groups	11254
group I , 1 × 106 NIMSCs -LRB- n = 7 -RRB- and in group II	11267
group I	11267
1 × 106 NIMSCs -LRB- n = 7 -RRB-	11276
1 ×	11276
106 NIMSCs -LRB- n = 7 -RRB-	11279
106 NIMSCs	11279
n	11291
7	11295
group	11305
II	11311
1 × 106 OECs -LRB- n = 7 -RRB-	11315
1 × 106 OECs	11315
n	11329
7	11333
the lesion site at three points -LRB- 5 µl at each site of injection -RRB-	11355
the lesion site	11355
three points -LRB- 5 µl at each site of injection -RRB-	11374
three points	11374
5 µl at each site of injection	11388
5 µl	11388
each site of injection	11396
each site	11396
injection	11409
the third group serving as control	11424
the third group	11424
control	11451
15 µl of medium with no cells	11460
15 µl	11460
medium with no cells	11469
medium	11469
no cells	11481
n = 7	11513
n	11513
= 7	11515
muscles and skin	11529
layers	11561
the completion of transplantation procedures	11579
the completion	11579
transplantation procedures	11597
viability of the cells	11625
viability	11625
the cells	11638
another aliquot in tissue culture flask	11675
another aliquot	11675
tissue culture flask	11694
them	11727
several days	11736
2.6	11750
Behavioral assessment The recovery of gross motor function	11755
Behavioral assessment The recovery	11755
Behavioral assessment	11755
The recovery	11777
gross motor function	11793
Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	11834
Basso -- Beattie -- Bresnahan	11834
Beattie	11840
BBB	11859
locomotor rating scale on the first day post injury and once per week	11864
locomotor rating scale	11864
the first day post injury and once per week	11890
the first day post injury	11890
once per week	11920
once	11920
week	11929
five weeks after cell transplantation	11949
five weeks	11949
cell transplantation	11966
BBB rating scale	11988
a range from complete paralysis -LRB- score 0 -RRB-	12012
a range	12012
complete paralysis -LRB- score 0 -RRB-	12025
complete paralysis	12025
score 0	12045
normal gait -LRB- score 21 -RRB- -LRB- Liebert , 1995 -RRB-	12057
normal gait -LRB- score 21 -RRB-	12057
normal gait	12057
score 21	12070
Liebert	12081
1995	12090
Locomotion	12097
digital video camera at each time point	12124
digital video camera	12124
each time point	12148
two blind researchers	12180
Statistical comparison between experimental groups	12203
Statistical comparison	12203
experimental groups	12234
repeated measures analysis of variance -LRB- ANOVA -RRB- followed by Dunnett T3 analysis as post hoc test , using SPSS version 13 -LRB- SPSS Inc. , Chicago , IL , USA -RRB-	12274
repeated measures	12274
analysis of variance -LRB- ANOVA -RRB-	12292
analysis	12292
variance -LRB- ANOVA -RRB-	12304
variance	12304
ANOVA	12314
Dunnett T3 analysis	12333
post hoc test	12356
SPSS version 13 -LRB- SPSS Inc. , Chicago , IL , USA -RRB-	12377
SPSS version 13	12377
SPSS Inc. , Chicago , IL , USA	12394
SPSS Inc.	12394
Chicago	12405
IL	12414
USA	12418
2.7	12424
Histological assessment Six weeks	12429
Histological assessment	12429
Six weeks	12453
injury	12469
five weeks post transplantation	12477
five weeks	12477
post transplantation	12488
all the rats	12511
70 mg/kg ketamine	12550
10 mg/kg xylazine	12569
4 % paraformaldehyde -LRB- PFA , 0.1 M , pH 7.4 -RRB-	12621
4 % paraformaldehyde	12621
PFA	12642
0.1 M	12647
pH 7.4	12654
The spinal cord	12663
overnight in 4 % PFA at 4 ◦ C. To carry out immunohistological analysis , the spinal cord was embedded in paraffin and sectioned longitudinally at 10 and 20 µm thicknesses ,	12705
overnight	12705
4 % PFA at 4 ◦ C. To carry out immunohistological analysis , the spinal cord was embedded in paraffin and sectioned longitudinally at 10 and 20 µm thicknesses ,	12718
4 % PFA	12718
4 ◦	12728
C.	12731
immunohistological analysis	12747
the spinal cord	12776
paraffin	12808
10 and 20 µm thicknesses	12849
a microtome	12878
Sections	12891
the presence of GFP positive NIMSC	12918
the presence	12918
GFP positive NIMSC	12934
anti GFP HorseRadish Peroxidase -LRB- HRP -RRB- conjugated antibody -LRB- 1/2000 , Abcam , USA -RRB- and also the presence of BrdU positive OECs , using anti BrdU HRP	12960
anti GFP HorseRadish Peroxidase	12960
HRP	12993
antibody -LRB- 1/2000 , Abcam , USA -RRB- and also the presence of BrdU positive OECs , using anti BrdU HRP	13009
antibody -LRB- 1/2000 , Abcam , USA -RRB-	13009
antibody	13009
1/2000	13019
Abcam	13027
USA	13034
the presence of BrdU positive OECs , using anti BrdU HRP	13048
the presence	13048
BrdU positive OECs	13064
anti BrdU HRP	13090
antibody -LRB- 1/2000 , AbD Serotec , USA -RRB-	13115
antibody	13115
1/2000	13125
AbD Serotec	13133
USA	13146
Samples	13152
light microscope	13180
diaminobenzidine -LRB- DAB -RRB- -LRB- Sigma , USA -RRB-	13210
diaminobenzidine -LRB- DAB -RRB-	13210
diaminobenzidine	13210
DAB	13228
Sigma	13234
USA	13241
The method of cavitation analysis	13247
The method	13247
cavitation analysis	13261
that previously described -LRB- Parr et al. , 2008 -RRB-	13308
that previously described	13308
that	13308
Parr	13335
et al. , 2008	13340
et al.	13340
2008	13348
Every eight sections from the spinal cord samples	13355
Every eight sections	13355
the spinal cord samples	13381
H&E staining	13424
The area of cavitation of each section	13438
The area	13438
cavitation of each section	13450
cavitation	13450
each section	13464
Image J software	13494
Any necrotic tissue within the cavities	13512
Any necrotic tissue	13512
the cavities	13539
part of the lesion	13567
part	13567
the lesion	13575
The total tissue area of the samples	13587
The total tissue area	13587
the samples	13612
5 mm rostral and caudal	13657
5 mm rostral	13657
caudal	13674
the injury epicenter covering a total of 1 cm of spinal cord	13684
the injury epicenter	13684
a total of 1 cm of spinal cord	13714
a total	13714
1 cm of spinal cord	13725
1 cm	13725
spinal cord	13733
The total cavity volume -LRB- Volcav -RRB- and total spinal cord volume -LRB- Voltotal -RRB-	13746
The total cavity volume -LRB- Volcav -RRB-	13746
The total cavity volume	13746
Volcav	13771
total spinal cord volume -LRB- Voltotal -RRB-	13783
total spinal cord volume	13783
Voltotal	13809
the percentage of cavitation -LRB- % Volcav -RRB-	13844
the percentage	13844
cavitation -LRB- % Volcav -RRB-	13862
cavitation	13862
% Volcav	13874
the following equation : % VolCav = Volcav/Voltotal × 100 %	13911
the following equation	13911
% VolCav = Volcav/Voltotal × 100 %	13935
% VolCav = Volcav/Voltotal ×	13935
assessment of axonal density	13973
assessment	13973
axonal density	13987
sections	14003
mouse monoclonal anti neurofilament 200 kD	14036
NF-200 , 1:1000 ; Sigma , USA	14080
NF-200	14080
1:1000 ; Sigma	14088
1:1000	14088
Sigma	14096
USA	14103
HRPconjugated secondary antibody and DAB	14142
The positively intact axons	14184
five random fields at 200 × magnification	14228
five random fields	14228
200 × magnification	14250
the epicenter of injury	14272
the epicenter	14272
injury	14289
Image J software	14302
Statistical comparison between experimental groups	14320
Statistical comparison	14320
experimental groups	14351
Kruskal -- Wallis test followed by appropriate post hoc test for k independent samples for the axon density values	14391
Kruskal	14391
Wallis test followed by appropriate post hoc test for k independent samples for the axon density values	14399
Wallis test	14399
appropriate post hoc test for k independent samples for the axon density values	14423
appropriate post hoc test for k independent samples	14423
k independent samples	14453
the axon density values	14479
Results	14508
1	14521
Characterization of transplanted cells .	14524
Characterization	14524
transplanted cells	14544
Determination of cell surface antigens by flow cytometry -LRB- A -RRB- .	14564
Determination	14564
cell surface antigens	14581
flow cytometry -LRB- A -RRB-	14606
flow cytometry	14606
A	14622
Phase-contrast microscopic image of undifferentiated MSC -LRB- B -RRB- , adipogenic -LRB- C -RRB- and osteogenic -LRB- D -RRB- differentiation of MSC .	14626
Phase-contrast microscopic image	14626
undifferentiated MSC -LRB- B -RRB- , adipogenic -LRB- C -RRB- and osteogenic -LRB- D -RRB- differentiation	14662
undifferentiated MSC -LRB- B -RRB-	14662
undifferentiated MSC	14662
B	14684
adipogenic -LRB- C -RRB-	14688
adipogenic	14688
C	14700
osteogenic -LRB- D -RRB- differentiation	14707
D	14719
MSC	14741
Phase-contrast micrographs of OEC -LRB- E -RRB- .	14746
Phase-contrast micrographs	14746
OEC -LRB- E -RRB-	14776
OEC	14776
E	14781
Fluorescent images of OECs	14785
Fluorescent images	14785
OECs	14807
DAPI -LRB- F -RRB- and anti-P75 antibody -LRB- G -RRB-	14825
DAPI	14825
F	14831
anti-P75 antibody	14838
G	14857
culture purity	14871
Scale bars	14887
100 µm	14908
Fig. 2 .	14917
Fig.	14917
2	14922
Fluorescent images of GFP	14925
Fluorescent images	14925
GFP	14947
undifferentiated MSC and immunostaining of NIMSC	14959
undifferentiated MSC and immunostaining	14959
NIMSC	15002
Nuclear staining of undifferentiated MSC -LRB- A -RRB- and GFP	15009
Nuclear staining	15009
undifferentiated MSC -LRB- A -RRB- and GFP	15029
undifferentiated MSC -LRB- A -RRB-	15029
undifferentiated MSC	15029
A	15051
GFP	15058
cells -LRB- B -RRB-	15070
cells	15070
B	15077
Merged image	15081
a transduction rate of 95 % -LRB- C -RRB-	15103
a transduction rate	15103
95 % -LRB- C -RRB-	15126
95 %	15126
C	15131
Light microscopic image of NIMSC -LRB- E -RRB- , MAP-2 -LRB- F -RRB- and - tubulin -LRB- G -RRB- immunostaining .	15135
Light microscopic image of NIMSC -LRB- E -RRB- , MAP-2 -LRB- F -RRB- and	15135
Light microscopic image	15135
NIMSC -LRB- E -RRB- , MAP-2 -LRB- F -RRB- and	15162
NIMSC -LRB- E -RRB-	15162
NIMSC	15162
E	15169
MAP-2 -LRB- F -RRB-	15173
MAP-2	15173
F	15180
tubulin -LRB- G -RRB- immunostaining	15189
tubulin	15189
G	15198
immunostaining	15201
Scale bars	15217
100 µm	15238
Fig. 3 .	15247
Fig.	15247
3	15252
images	15264
videos	15276
hindlimb posture in animals	15288
hindlimb posture	15288
animals	15308
cell transplantation -LRB- week 0 -RRB-	15323
cell transplantation	15323
week 0	15345
the end of study -LRB- week 6 -RRB- in the three studied groups -LRB- control , OEC and NIMSC -RRB-	15360
the end	15360
study -LRB- week 6 -RRB- in the three studied groups -LRB- control , OEC and NIMSC -RRB-	15371
study -LRB- week 6 -RRB-	15371
study	15371
week 6	15378
the three studied groups	15389
the three	15389
groups	15407
control , OEC and NIMSC	15415
control	15415
OEC and NIMSC	15424
Fig. 4 .	15441
Fig.	15441
4	15446
Weekly improvements in animal hindlimb motor function during study	15449
Weekly improvements	15449
animal hindlimb motor function during study	15472
animal hindlimb motor function	15472
study	15510
BBB	15528
system	15540
Scores in NIMSC group	15548
Scores	15548
NIMSC group	15558
OEC and control group	15600
P <	15624
P	15624
<	15626
0.05	15628
OEC group	15635
a significantly higher BBB score	15659
control group -LRB- * P < 0.05 -RRB-	15697
control group	15697
P <	15713
P	15713
<	15715
0.05	15717
Data	15724
the means	15746
SD	15758
Fig. 5 .	15763
Fig.	15763
5	15768
Weekly survival diagram	15771
the dead animals	15804
the course of study	15828
the course	15828
study	15842
Fig. 6 .	15850
Fig.	15850
6	15855
Detection of the	15858
Detection	15858
the	15871
transplanted cells in the injured tissue	15883
transplanted cells	15883
the injured tissue	15905
Light microscopic images of GFP positive cells -LRB- NIMSC -RRB- -LRB- A -RRB- and BrdU positive cells -LRB- OEC -RRB- -LRB- B -RRB- in the injured parenchyma tissue , five weeks after transplantation using HRP	15925
Light microscopic images	15925
GFP positive cells -LRB- NIMSC -RRB- -LRB- A -RRB- and BrdU positive cells -LRB- OEC -RRB-	15953
GFP positive cells -LRB- NIMSC -RRB- -LRB- A -RRB-	15953
GFP positive cells -LRB- NIMSC -RRB-	15953
GFP positive cells	15953
NIMSC	15973
A	15981
BrdU positive cells -LRB- OEC -RRB-	15988
BrdU positive cells	15988
OEC	16009
B	16015
the injured parenchyma tissue , five weeks after transplantation using HRP	16021
the injured parenchyma tissue	16021
five weeks after transplantation using HRP	16052
five weeks	16052
transplantation using HRP	16069
transplantation	16069
HRP	16091
antibody	16106
Scale bars	16116
100 µm	16137
Fig. 7 .	16146
Fig.	16146
7	16151
Light microscopic images of cavity formation in the three -LRB- control , OEC and NIMSC -RRB- groups -LRB- A -RRB- .	16154
Light microscopic images	16154
cavity formation	16182
the three -LRB- control , OEC and NIMSC -RRB- groups -LRB- A -RRB-	16202
the three -LRB- control , OEC and NIMSC -RRB-	16202
the three	16202
control , OEC and NIMSC	16213
control	16213
OEC and NIMSC	16222
groups -LRB- A -RRB-	16237
groups	16237
A	16245
The percentage of area occupied with syrinx cavity .	16249
The percentage	16249
area occupied with syrinx cavity	16267
area	16267
syrinx cavity	16286
the OEC and NIMSC groups	16304
cavity formation	16330
the control group	16375
P <	16395
P	16395
<	16397
0.05	16399
The difference between percentage of cavitation in NIMSC and OEC groups	16406
The difference	16406
percentage of cavitation in NIMSC and OEC groups	16429
percentage	16429
cavitation in NIMSC and OEC groups	16443
cavitation	16443
NIMSC and OEC groups	16457
P > 0.05	16513
P	16513
> 0.05	16515
>	16515
0.05	16517
B	16524
Data	16528
the means	16550
SD	16562
Scale bars	16566
100 µm	16587
Fig. 8 .	16596
Fig.	16596
8	16601
Light microscopic images showing NF-positive axons in all studied groups -LRB- control , OEC and NIMSC -RRB- -LRB- A -RRB- .	16604
Light microscopic images	16604
NF-positive axons	16637
all studied groups -LRB- control , OEC and NIMSC -RRB- -LRB- A -RRB-	16658
all	16658
groups -LRB- control , OEC and NIMSC -RRB- -LRB- A -RRB-	16670
groups -LRB- control , OEC and NIMSC -RRB-	16670
groups	16670
control , OEC and NIMSC	16678
control	16678
OEC and NIMSC	16687
A	16703
Percentage of NF-positive axons in injured area .	16707
Percentage	16707
NF-positive axons	16721
injured area	16742
NIMSC group	16756
significantly more positive axons compared to the other two groups -LRB- * P < 0.05 -RRB-	16772
significantly more positive axons	16772
the other two groups -LRB- * P < 0.05 -RRB-	16818
the other two groups	16818
P <	16841
P	16841
<	16843
0.05	16845
the number of NF-IR positive axons in the OEC treated group	16862
the number	16862
NF-IR positive axons in the OEC treated group	16876
NF-IR positive axons	16876
the OEC treated group	16900
the OEC	16900
group	16916
the control group -LRB- * P < 0.05 -RRB- -LRB- B -RRB-	16953
the control group -LRB- * P < 0.05 -RRB-	16953
the control group	16953
P <	16973
P	16973
<	16975
0.05	16977
B	16984
Data	16988
the means	17010
S.D. Scale bars	17022
100 µm	17048
3.1	17057
MSCs and OECs characterization Surface markers of fibroblast-like cells isolated from bone marrow	17062
MSCs and OECs	17062
characterization Surface markers of fibroblast-like cells	17076
characterization Surface markers	17076
fibroblast-like cells	17112
bone marrow	17148
flowcytometry analysis	17180
Data	17204
the expression of cell surface antigens such as CD90 and CD73	17221
the expression	17221
cell surface antigens such as CD90 and CD73	17239
cell surface antigens	17239
CD90 and CD73	17269
they	17303
negative for CD31 , CD44 , CD45 -LRB- Fig. 1A -RRB-	17313
negative for CD31 , CD44 , CD45	17313
CD31 , CD44 ,	17326
CD31	17326
CD44	17332
Fig. 1A	17344
The formation of oil droplets and calcium depositions stained with Oil Red O and Alizarin Red	17354
The formation	17354
oil droplets and calcium depositions stained with Oil Red O and Alizarin Red	17371
oil droplets and calcium depositions	17371
Oil Red O and Alizarin Red	17421
the multilineage differentiation potential of the isolated mesenchymal cells -LRB- Fig. 1B -- D -RRB-	17472
the multilineage differentiation potential	17472
the isolated mesenchymal cells -LRB- Fig. 1B -- D -RRB-	17518
the isolated mesenchymal cells	17518
Fig. 1B -- D	17550
Fig. 1B	17550
D	17558
OECs present low affinity NGF receptor -LRB- P75 -RRB- on their cell surfaces .	17562
OECs	17562
present low affinity NGF receptor -LRB- P75 -RRB- on their cell surfaces	17567
present low affinity NGF receptor -LRB- P75 -RRB-	17567
present low affinity NGF receptor	17567
P75	17602
their cell surfaces	17610
the purification of the enriched population	17641
the purification	17641
the enriched population	17661
cells	17686
anti-P75 antibody	17710
Merged images	17729
majority of the cells -LRB- > 95 % -RRB-	17755
majority	17755
the cells -LRB- > 95 % -RRB-	17767
the cells	17767
> 95 %	17778
>	17778
95 %	17779
this marker -LRB- Fig. 1E -- G -RRB-	17802
this marker	17802
Fig. 1E -- G	17815
Fig. 1E	17815
G	17823
MSCs	17840
cells	17846
GFP bearing lentiviral vectors	17873
Percentage of tranduced cells	17905
Percentage	17905
tranduced cells	17919
fluorescent microscope and DAPI nuclear staining	17956
fluorescent microscope	17956
DAPI nuclear staining	17983
more	18014
than75 % of the cells to be positive for GFP -LRB- Fig. 2A -- C -RRB-	18019
than75 %	18019
the cells	18030
GFP	18059
Fig. 2A -- C	18064
Fig. 2A	18064
C	18072
3.2	18076
NIMSCs characterization	18081
the MSCs	18116
neural lineage	18132
their morphology	18147
a day	18187
The cells	18194
characteristic round cell bodies	18214
several branching extensions	18252
Approximately 30 % of the cell population	18282
Approximately 30 %	18282
the cell population	18303
shape	18352
contact	18379
neighboring cells	18392
7 days of culture in neurogenic media	18417
7 days	18417
culture in neurogenic media	18427
culture	18427
neurogenic media	18438
the cells	18456
neural markers : MAP2 and beta-tubulin III which verified the production of these neural cytoskeletal proteins in the differentiated cells -LRB- Fig. 2D -- F -RRB-	18484
neural markers	18484
MAP2 and beta-tubulin III which verified the production of these neural cytoskeletal proteins in the differentiated cells -LRB- Fig. 2D -- F -RRB-	18500
MAP2	18500
beta-tubulin III which verified the production of these neural cytoskeletal proteins in the differentiated cells -LRB- Fig. 2D -- F -RRB-	18509
beta-tubulin III	18509
the production of these neural cytoskeletal proteins	18541
the production	18541
these neural cytoskeletal proteins	18559
the differentiated cells	18597
the	18597
cells	18616
Fig. 2D -- F	18623
Fig. 2D	18623
F	18631
We	18635
neurally induced rat MSCs	18664
both immature -LRB- Nestin and beta-tubulin III -RRB- and mature -LRB- NSE and MAP2 -RRB- neuronal markers but not glial markers -LRB- GFAP -RRB- -LRB- Pedram et al. , 2009 -RRB-	18698
immature -LRB- Nestin and beta-tubulin III -RRB-	18703
immature	18703
Nestin and beta-tubulin III	18713
Nestin	18713
beta-tubulin III	18724
mature -LRB- NSE and MAP2 -RRB- neuronal markers but not glial markers -LRB- GFAP -RRB- -LRB- Pedram et al. , 2009 -RRB-	18746
mature -LRB- NSE and MAP2 -RRB- neuronal markers	18746
NSE and MAP2	18754
NSE	18754
MAP2	18762
not glial markers -LRB- GFAP -RRB- -LRB- Pedram et al. , 2009 -RRB-	18789
not glial markers -LRB- GFAP -RRB-	18789
not glial markers	18789
GFAP	18808
Pedram	18815
et al. , 2009	18822
et al.	18822
2009	18830
3.3	18837
Functional improvements	18842
We	18866
the recovery of hindlimb function using BBB scale , in which the maximum hindlimb motor function score was 21	18878
the recovery	18878
hindlimb function using BBB scale , in which the maximum hindlimb motor function score was 21	18894
hindlimb function	18894
BBB scale , in which the maximum hindlimb motor function score was 21	18918
BBB scale	18918
the maximum hindlimb motor function score	18938
the maximum hindlimb	18938
motor function score	18959
21	18984
All rats	18988
a score of 21	19001
a score	19001
21	19012
the injury	19029
the scores	19044
0 -- 1 soon after the compression	19071
0 -- 1	19071
the compression	19086
We	19103
OECs , NIMSCs or pure medium	19119
OECs	19119
NIMSCs	19125
pure medium	19135
the spinal cord 7 days	19152
the spinal cord	19152
7 days	19168
injury	19181
the rats subjected to contusion and then injected with NIMSCs	19192
the rats	19192
contusion	19214
NIMSCs	19247
BBB score	19255
14.25	19278
± 1.69 , in a five week interval from the time of transplantation while this score was 8.625 ± 1.03 in the OEC treated group and 7.375 ± 0.916 in the control ones	19284
± 1.69	19284
a five week interval from the time of transplantation while this score was 8.625 ± 1.03 in the OEC treated group and 7.375 ± 0.916 in the control ones	19295
a five week interval	19295
the time of transplantation	19321
the time	19321
transplantation	19333
this score	19355
8.625 ± 1.03 in the OEC treated group and 7.375 ± 0.916 in the control ones	19370
8.625 ±	19370
1.03 in the OEC treated group and 7.375	19378
1.03	19378
the OEC treated group and 7.375	19386
the OEC	19386
group and 7.375	19402
group	19402
7.375	19412
0.916	19420
the control ones	19429
functional terms	19450
the contused rats in NIMSC group	19468
the contused rats	19468
NIMSC group	19489
consistent weight	19517
plantar steps	19545
forelimb and hindlimb coordination	19564
rats in OEC treated group	19611
rats	19611
OEC treated group	19619
no weigh support	19656
rats in the control group	19683
rats	19683
the control group	19691
all three joint	19720
they	19749
sweep	19773
planter step -LRB- Fig. 3 , Supplementary videos 1 -- 6 -RRB-	19785
planter step	19785
Fig. 3 , Supplementary videos 1 -- 6	19799
Fig. 3 , Supplementary videos	19799
Fig. 3	19799
Supplementary videos	19807
1 -- 6	19828
The improvement of locomotor function in NIMSC group	19834
The improvement	19834
locomotor function in NIMSC group	19853
locomotor function	19853
NIMSC group	19875
OEC and control groups	19917
P < 0.05	19941
P	19941
< 0.05	19943
<	19943
0.05	19945
OEC group	19963
a significantly higher BBB score	19987
control group	20025
five weeks -LRB- P < 0.05 -RRB- -LRB- Fig. 4 -RRB-	20045
five weeks -LRB- P < 0.05 -RRB-	20045
P < 0.05	20057
P	20057
< 0.05	20059
<	20059
0.05	20061
Fig. 4	20068
all groups	20094
most of the locomotor function improvements	20106
most	20106
the locomotor function improvements	20114
the first week	20166
The control and treated groups	20182
The control	20182
treated groups	20198
a steady recovery that had been approximately plateaued by the fifth week , which was the end point of the experiment -LRB- Fig. 4 -RRB-	20223
a steady recovery	20223
the fifth week , which was the end point of the experiment -LRB- Fig. 4 -RRB-	20282
the fifth week	20282
the end point of the experiment -LRB- Fig. 4 -RRB-	20308
the end point	20308
the experiment -LRB- Fig. 4 -RRB-	20325
the experiment	20325
Fig. 4	20341
3.4	20350
Mortality rate of animals Rate of mortality in cell treated groups	20355
Mortality rate	20355
animals Rate of mortality in cell treated groups	20373
animals Rate	20373
mortality in cell treated groups	20389
mortality	20389
cell treated groups	20402
control group	20441
the first and second week post transplantation	20467
2 rats	20514
the control group	20531
each week	20552
the course of follow up in the NIMSC treated group no rat	20577
the course	20577
the NIMSC treated group no rat	20604
the NIMSC	20604
group	20622
no rat	20628
the OEC treated group	20643
the OEC	20643
group	20659
only one rat	20665
the first week -LRB- Fig. 5 -RRB-	20686
the first week	20686
Fig. 5	20702
addition	20714
the end of the study rats	20751
the end	20751
the study rats	20762
cell treatment	20787
a better hygiene and health status	20806
a better hygiene	20806
health status	20827
the control group -LRB- not shown -RRB-	20846
the control group	20846
3.5	20877
transplanted cells	20890
tissue	20912
Five weeks	20919
transplantation	20936
paraffin-embedded tissue sections	20953
GFP	21011
BrdU stained cells using HRP conjugated secondary antibody against GFP and BrdU	21028
BrdU	21028
cells	21041
HRP	21053
secondary antibody	21068
GFP and BrdU	21095
GFP	21095
BrdU	21103
The positive cells	21109
the parenchyma of the analyzed tissues -LRB- Fig. 6 -RRB-	21152
the parenchyma	21152
the analyzed tissues -LRB- Fig. 6 -RRB-	21170
the analyzed tissues	21170
Fig. 6	21192
3.6	21201
Cavitation analysis The percentage of cavitation	21206
Cavitation analysis The percentage	21206
Cavitation analysis	21206
The percentage	21226
cavitation	21244
H&E staining -LRB- Fig. 7A -RRB-	21276
H&E staining	21276
Fig. 7A	21290
Data	21300
cavitation area	21317
NIMSC and OEC treated groups	21359
NIMSC	21359
OEC treated groups	21369
comparison with control group -LRB- P < 0.05 -RRB-	21391
comparison	21391
control group -LRB- P < 0.05 -RRB-	21407
control group	21407
P < 0.05	21422
P	21422
< 0.05	21424
<	21424
0.05	21426
the percentage of cavitaion in NIMSC treated group	21442
the percentage	21442
cavitaion in NIMSC treated group	21460
cavitaion	21460
NIMSC treated group	21473
a slight decrease	21500
OEC group but this difference	21530
OEC group	21530
this difference	21544
P > 0.05	21595
P	21595
> 0.05	21597
>	21597
0.05	21599
Fig. 7B	21606
3.7	21616
Axonal regeneration	21621
We	21641
HRP conjugated anti-neurofilament antibody to evaluate axonal density -LRB- Fig. 8A -RRB-	21649
HRP	21649
anti-neurofilament antibody	21664
axonal density -LRB- Fig. 8A -RRB-	21704
axonal density	21704
Fig. 8A	21720
The number of NF-immunoreactive -LRB- IR -RRB- axons	21730
The number	21730
NF-immunoreactive -LRB- IR -RRB- axons	21744
IR	21763
NIMSC treated groups	21801
OEC treated and control groups -LRB- P < 0.05 -RRB-	21834
OEC treated	21834
OEC	21834
control groups -LRB- P < 0.05 -RRB-	21850
control groups	21850
P < 0.05	21866
P	21866
< 0.05	21868
<	21868
0.05	21870
the number of NF-IR positive axons in the OEC treated group	21887
the number	21887
NF-IR positive axons in the OEC treated group	21901
NF-IR positive axons	21901
the OEC treated group	21925
the OEC	21925
group	21941
the control group -LRB- P < 0.05 -RRB- -LRB- Fig. 8B -RRB-	21978
the control group -LRB- P < 0.05 -RRB-	21978
the control group	21978
P < 0.05	21997
P	21997
< 0.05	21999
<	21999
0.05	22001
Fig. 8B	22008
Discussion The present study	22022
Discussion	22022
The present study	22033
the capacity of differentiation of BMSCs	22061
the capacity	22061
differentiation of BMSCs	22077
differentiation	22077
BMSCs	22096
neuron	22107
cells and ability of these cells	22119
cells and ability	22119
these cells	22140
SCI in both behavioral and histological aspects	22163
SCI	22163
both behavioral and histological aspects	22170
great promises	22220
the translation of MSC research	22239
the translation	22239
MSC research	22258
the clinics	22276
Our results	22289
better outcomes	22308
NIMSC	22333
OECs	22344
This work	22350
continuation of our previous study in which we demonstrated that in rat SCI model , neurally induced MSCs could bring out far better outcomes in terms of behavioral improvements relative to non induced MSCs -LRB- Pedram et al. , 2009 -RRB-	22367
continuation	22367
our previous study in which we demonstrated that in rat SCI model , neurally induced MSCs could bring out far better outcomes in terms of behavioral improvements relative to non induced MSCs -LRB- Pedram et al. , 2009 -RRB-	22383
our previous study	22383
we	22411
rat	22435
SCI model , neurally	22439
SCI model	22439
MSCs	22467
far better outcomes	22488
terms of behavioral improvements	22511
terms	22511
behavioral improvements	22520
non induced MSCs	22556
Pedram	22574
et al. , 2009	22581
et al.	22581
2009	22589
Our results	22596
the enormous capacity of NIMSC	22620
the enormous capacity	22620
NIMSC	22645
the injured tissue	22665
their role	22695
the cavitation	22718
axonal growth	22747
motor performance , some outcomes that were not achieved to the same extent by OEC	22788
motor performance	22788
some outcomes that were not achieved to the same extent by OEC	22807
some outcomes	22807
the same extent	22847
OEC	22866
Several methods	22871
about spinal damage	22911
animal models	22934
this study	22952
we	22964
the pressure method	22977
Fogarty catheter	23003
The best injury models for spinal regeneration by cell therapy	23021
The best injury models	23021
spinal regeneration by cell therapy	23048
spinal regeneration	23048
cell therapy	23071
those showing improvement over time	23088
those showing improvement	23088
time	23119
Vanicky et al.	23125
Vanicky	23125
et al.	23133
this much of pressure per weight of rats	23183
this much	23183
pressure per weight of rats	23196
pressure	23196
weight of rats	23209
weight	23209
rats	23219
some degrees of improvement	23225
some degrees	23225
improvement	23241
time	23270
They	23276
five weeks of damage	23302
five weeks	23302
damage	23316
the score	23323
0 -- 1 to about 8.5 -LRB- Vanicky ' et al. , 2001 -RRB-	23352
0 -- 1	23352
about 8.5 -LRB- Vanicky ' et al. , 2001 -RRB-	23359
about 8.5	23359
Vanicky ' et al. , 2001	23370
Vanicky '	23370
et al.	23379
2001	23387
our study , five weeks post transplantation	23397
our study	23397
five weeks post transplantation	23408
five weeks	23408
the score of control group	23440
the score	23440
control group	23453
7.3 , which is pretty close to the result mentioned in study of Vanicky et al.	23484
7.3	23484
the result	23514
study of Vanicky	23538
study	23538
Vanicky	23547
et al.	23555
This lower value	23562
variations between animals	23595
variations	23595
animals	23614
reoperation and negligible damage	23623
reoperation	23623
negligible damage	23639
the time of medium injection	23667
the time	23667
medium injection	23679
Changes happening in the CNS microenvironment after a lesion , namely release of inhibitory molecules from the central myelin as well as proteoglycans associated with astroglial scarring , limit the spontaneous reorganization of the neural pathways and inhibit effective regeneration -LRB- Camand et al. , 2004 ; Yiu and He , 2006 -RRB- .	23697
Changes	23697
the CNS microenvironment	23718
a lesion , namely release of inhibitory molecules from the central myelin as well as proteoglycans associated with astroglial scarring ,	23749
a lesion	23749
namely release of inhibitory molecules from the central myelin as well as proteoglycans associated with astroglial scarring	23759
namely release of inhibitory molecules from the central myelin	23759
namely release	23759
inhibitory molecules from the central myelin	23777
inhibitory molecules	23777
the central myelin	23803
proteoglycans associated with astroglial scarring	23833
proteoglycans	23833
astroglial scarring	23863
the spontaneous reorganization of the neural pathways	23890
the spontaneous reorganization	23890
the neural pathways	23924
effective regeneration -LRB- Camand et al. , 2004 ; Yiu and He , 2006 -RRB-	23956
effective regeneration	23956
Camand et al. , 2004 ; Yiu and He , 2006	23980
Camand et al.	23980
Camand	23980
et al.	23987
2004 ; Yiu	23995
2004	23995
Yiu	24001
He , 2006	24009
He	24009
2006	24013
Cell	24020
therapies aiming at repairing SCI can affect histological and functional outcomes in two different ways : -LRB- 1 -RRB- by differentiation and functional integration of neuron-like or oligodendrocyte-like cells into the spared spinal cord circuitry -LRB- replacement approach -RRB- , -LRB- 2 -RRB- by increasing host cellular or axonal survival or decreasing host glial scaring and increasing regeneration or remyelination of injured axons through neuromodulatory transmitters -LRB- regenerative approach -RRB- -LRB- Cummings et al. , 2005 -RRB- .	24031
therapies	24031
SCI	24061
histological and functional outcomes	24076
two different ways : -LRB- 1 -RRB- by differentiation and functional integration of neuron-like or oligodendrocyte-like cells into the spared spinal cord circuitry -LRB- replacement approach -RRB-	24116
two different ways	24116
-LRB- 1 -RRB- by differentiation and functional integration of neuron-like or oligodendrocyte-like cells into the spared spinal cord circuitry -LRB- replacement approach -RRB-	24136
by	24140
differentiation and functional integration	24143
neuron-like or oligodendrocyte-like cells into the spared spinal cord circuitry -LRB- replacement approach -RRB-	24189
neuron-like or oligodendrocyte-like cells	24189
the spared spinal cord circuitry -LRB- replacement approach -RRB-	24236
the spared spinal cord circuitry	24236
replacement approach	24270
host cellular or axonal survival or decreasing host	24311
host cellular or axonal survival	24311
decreasing host	24347
regeneration or remyelination of injured axons	24392
regeneration or remyelination	24392
injured axons	24425
neuromodulatory transmitters -LRB- regenerative approach -RRB- -LRB- Cummings et al. , 2005 -RRB-	24447
neuromodulatory transmitters -LRB- regenerative approach -RRB-	24447
neuromodulatory transmitters	24447
regenerative approach	24477
Cummings	24501
et al. , 2005	24510
et al.	24510
2005	24518
Stem cells	24525
lost cells	24548
neuroprotection and permissive neurotrophic factors and substrates	24575
axonal regeneration	24646
transplantation	24672
the injured central nervous system -LRB- Novikova et al. , 2011a ; Reier , 2004 -RRB-	24693
the injured central nervous system	24693
Novikova	24729
et al. , 2011a ; Reier , 2004	24738
et al.	24738
2011a ; Reier	24746
2011a	24746
Reier	24753
2004	24760
Many studies	24767
a population of progenitor cells	24804
a population	24804
progenitor cells	24820
the spinal damaged tissue	24855
they	24882
environmental stimuli	24904
glial cells	24949
neurons -LRB- Castro et al. , 2002 -RRB-	24971
neurons	24971
Castro	24980
et al. , 2002	24987
et al.	24987
2002	24995
Li et al.	25002
Li	25002
et al.	25005
nestin positive precursor cells in outer-root sheath of hair follicles and Amoh et al. demonstrated that these cells can differentiate into neurons , glia , keratinocytes , smooth muscle cells , and melanocytes in vitro -LRB- Amoh et al. , 2005b ; Li et al. , 2003 -RRB-	25019
nestin positive precursor cells in outer-root sheath of hair follicles and Amoh et al. demonstrated that these cells can differentiate into neurons , glia , keratinocytes , smooth muscle cells , and melanocytes in vitro	25019
nestin	25019
positive precursor cells in outer-root sheath of hair follicles and Amoh et al.	25026
positive precursor cells	25026
outer-root sheath of hair follicles and Amoh et al.	25054
outer-root sheath of hair follicles	25054
outer-root sheath	25054
hair follicles	25075
Amoh et al.	25094
Amoh	25094
et al.	25099
these cells	25124
neurons , glia , keratinocytes , smooth muscle cells , and melanocytes	25159
neurons	25159
glia	25168
keratinocytes	25174
smooth muscle cells	25189
melanocytes	25214
Amoh	25236
et al. , 2005b ; Li et al. , 2003	25241
et al.	25241
2005b ; Li et al.	25249
2005b	25249
Li et al.	25256
Li	25256
et al.	25259
2003	25267
They	25274
hair follicle stem cells transplanted into sciatic injured nerve	25286
hair follicle stem cells	25286
sciatic injured nerve	25329
spinal cord lesion , largely transdifferentiate to schwann cells ,	25355
spinal cord lesion	25355
schwann cells	25405
the rate of nerve regeneration	25428
the rate	25428
nerve regeneration	25440
the sciatic nerve and spinal cord function -LRB- Amoh et al. , 2005a , 2008 -RRB-	25471
the sciatic nerve and spinal cord function	25471
Amoh	25515
et al. , 2005a , 2008	25520
et al.	25520
2005a	25528
2008	25535
bulge area	25551
origin of these nestin-expressing pluripotent stem cells -LRB- Uchugonova et al. , 2011a -RRB-	25578
origin	25578
these nestin-expressing pluripotent stem cells -LRB- Uchugonova et al. , 2011a -RRB-	25588
these nestin-expressing pluripotent stem cells	25588
Uchugonova	25636
et al. , 2011a	25647
et al.	25647
2011a	25655
induction of stem cells before transplantation or using neural restricted progenitor cells	25674
induction	25674
stem cells before transplantation or using neural restricted progenitor cells	25687
stem cells before transplantation	25687
stem cells	25687
transplantation	25705
neural restricted progenitor cells	25730
a useful method for neuron replacement in the injured CNS -LRB- Lepore et al. , 2004 ; Lu et al. , 2006 ; Ye et al. , 2007 -RRB-	25788
a useful method	25788
neuron replacement in the injured CNS -LRB- Lepore et al. , 2004 ; Lu et al. , 2006 ; Ye et al. , 2007 -RRB-	25808
neuron replacement	25808
the injured CNS -LRB- Lepore et al. , 2004 ; Lu et al. , 2006 ; Ye et al. , 2007 -RRB-	25830
the injured CNS	25830
Lepore et al. , 2004 ; Lu et al. , 2006 ; Ye et al. , 2007	25847
Lepore	25847
et al. , 2004 ; Lu et al. , 2006 ; Ye et al. , 2007	25854
et al. , 2004	25854
et al.	25854
2004	25862
Lu et al. , 2006	25868
Lu	25868
et al. , 2006	25871
et al.	25871
2006	25879
Ye et al. , 2007	25885
Ye	25885
et al. , 2007	25888
et al.	25888
2007	25896
Useful effects of neurally pre-differentiated embryonic and neural restricted stem cells on spinal cord regeneration	25903
Useful effects	25903
neurally pre-differentiated embryonic and neural restricted stem cells on spinal cord regeneration	25921
neurally pre-differentiated embryonic and neural restricted stem cells	25921
spinal cord regeneration	25995
previous studies -LRB- Han et al. , 2002 ; Marques et al. , 2010 -RRB-	26049
previous studies	26049
Han	26067
et al. , 2002 ; Marques et al. , 2010	26071
et al.	26071
2002 ; Marques et al.	26079
2002	26079
Marques et al.	26085
Marques	26085
et al.	26093
2010	26101
Lu et al.	26108
Lu	26108
et al.	26111
the efficacy of pre-differentiated adult bone marrow cells	26132
the efficacy	26132
pre-differentiated adult bone marrow cells	26148
functional recovery	26194
rats following traumatic brain injury -LRB- Lu et al. , 2006 -RRB-	26217
rats	26217
traumatic brain injury -LRB- Lu et al. , 2006 -RRB-	26232
traumatic brain injury	26232
Lu	26256
et al. , 2006	26259
et al.	26259
2006	26267
Lin et al.	26274
Lin	26274
et al.	26278
schwann cells and neurons which were induced from rat hair follicle neural crest stem cell could survive in the nerve constructs as long as eight weeks	26292
schwann cells and neurons	26292
rat hair follicle neural crest stem cell could survive in the nerve constructs as long as eight weeks	26342
rat hair follicle	26342
neural crest stem cell	26360
the nerve constructs as long as eight weeks	26400
the nerve constructs	26449
desirable electrophysiological features -LRB- Lin et al. , 2011 -RRB-	26477
desirable electrophysiological features	26477
Lin	26518
et al. , 2011	26522
et al.	26522
2011	26530
Our observations	26537
neurally induced MSCs	26569
neuronal morphologic characteristics	26601
small , refractile somata , multiple long processes and also expression of neuron specific markers -LRB- MAP2 and beta-tubulin -RRB-	26648
small , refractile somata	26648
multiple long processes	26674
expression of neuron specific markers -LRB- MAP2 and beta-tubulin -RRB-	26707
expression	26707
neuron specific markers -LRB- MAP2 and beta-tubulin -RRB-	26721
neuron specific markers	26721
MAP2 and beta-tubulin	26746
MAP2	26746
beta-tubulin	26755
a short term in vitro induction	26775
short term	26777
An important issue in cell based therapy	26808
An important issue	26808
cell based therapy	26830
cell	26830
therapy	26841
the survival of the grafted cells	26852
the survival	26852
the grafted cells	26868
injection	26894
we	26905
OECs	26916
BrdU	26927
them	26949
the target tissue	26957
the end of study	26978
the end	26978
study	26989
GFP labeled NIMSCs	27006
GFP	27006
NIMSCs	27018
the injured tissue	27046
the ability of these cells	27074
the ability	27074
these cells	27089
the spinal tissue of recipient rats	27119
the spinal tissue	27119
recipient rats	27140
New methods of noninvasive long-term in vivo tracking of intra-tissue stem cells	27156
New methods	27156
noninvasive long-term in vivo tracking of intra-tissue stem cells	27171
noninvasive long-term	27171
tracking of intra-tissue stem cells	27201
tracking	27201
intra-tissue stem cells	27213
long-term fate of transplanted cells -LRB- Uchugonova et al. , 2011b -RRB-	27263
long-term fate	27263
transplanted cells -LRB- Uchugonova et al. , 2011b -RRB-	27281
transplanted cells	27281
Uchugonova	27301
et al. , 2011b	27312
et al.	27312
2011b	27320
The role and function of differentiated cells in functional and behavioral improvements of spinal cord injuries	27328
The role and function	27328
cells in functional and behavioral improvements of spinal cord injuries	27368
cells	27368
functional and behavioral improvements of spinal cord injuries	27377
functional and behavioral improvements	27377
spinal cord injuries	27419
the grafted cells ' processes making synaptic connections with the processes of endogenous neurons -LRB- Lepore et al. , 2006 -RRB-	27468
the grafted cells ' processes	27468
the grafted cells '	27468
synaptic connections	27504
the processes of endogenous neurons -LRB- Lepore et al. , 2006 -RRB-	27530
the processes	27530
endogenous neurons -LRB- Lepore et al. , 2006 -RRB-	27547
endogenous neurons	27547
Lepore	27567
et al. , 2006	27574
et al.	27574
2006	27582
Other studies	27589
neuronal differentiation , synapse formation and electrophysiological connectivity	27614
neuronal differentiation	27614
synapse formation	27640
electrophysiological connectivity	27662
transplantation of neural precursor cells -LRB- Auerbach et al. , 2000 ; Cummings et al. , 2005 ; Wernig et al. , 2004 -RRB-	27702
transplantation	27702
neural precursor cells -LRB- Auerbach et al. , 2000 ; Cummings et al. , 2005 ; Wernig et al. , 2004 -RRB-	27721
neural precursor cells	27721
Auerbach et al. , 2000 ; Cummings et al. , 2005 ; Wernig et al. , 2004	27745
Auerbach	27745
et al. , 2000 ; Cummings et al. , 2005 ; Wernig et al. , 2004	27754
et al. , 2000	27754
et al.	27754
2000	27762
Cummings et al. , 2005	27768
Cummings	27768
et al. , 2005	27777
et al.	27777
2005	27785
Wernig et al. , 2004	27791
Wernig	27791
et al. , 2004	27798
et al.	27798
2004	27806
Another important possible cause of the increase in axonal density and better functional outcome in neurally induced stem cell group	27813
Another important possible cause	27813
the increase in axonal density and better functional outcome in neurally induced stem cell group	27849
axonal density and better functional outcome	27865
axonal density	27865
better functional outcome	27884
neurally induced stem	27913
the MSCs	27954
neurotrophic factors that would either enhance axonal growth in surviving neurons or help rescue axons from Wallerian degeneration after injury -LRB- Novikova et al. , 2011a -RRB-	27977
neurotrophic factors	27977
axonal growth	28024
surviving neurons	28041
rescue axons	28067
Wallerian degeneration	28085
injury -LRB- Novikova et al. , 2011a -RRB-	28114
injury	28114
Novikova	28122
et al. , 2011a	28131
et al.	28131
2011a	28139
It	28147
the synaptic connections , secretion of neurotrophic factors	28172
the synaptic connections	28172
secretion of neurotrophic factors	28198
secretion	28198
neurotrophic factors	28211
growth factor alfa -LRB- TGF-alfa -RRB- and brain-derived neurotrophic factor -LRB- BDNF -RRB-	28255
growth factor alfa -LRB- TGF-alfa -RRB-	28255
growth factor alfa	28255
TGF-alfa	28275
brain-derived neurotrophic factor -LRB- BDNF -RRB-	28289
brain-derived neurotrophic factor	28289
BDNF	28324
transplanted differentiated cells could contribute to functional recovery -LRB- Kerr et al. , 2003 -RRB-	28336
transplanted	28336
cells	28364
functional recovery -LRB- Kerr et al. , 2003 -RRB-	28390
functional recovery	28390
Kerr	28411
et al. , 2003	28416
et al.	28416
2003	28424
Improvement in functional results	28431
Improvement	28431
functional results	28446
this fact	28479
grafted stem cells	28494
increased survival of neurons and axons and formation of new connections -LRB- Cummings et al. , 2005 -RRB-	28525
increased survival of neurons and axons	28525
increased survival	28525
neurons and axons	28547
formation of new connections -LRB- Cummings et al. , 2005 -RRB-	28569
formation	28569
new connections -LRB- Cummings et al. , 2005 -RRB-	28582
new connections	28582
Cummings	28599
et al. , 2005	28608
et al.	28608
2005	28616
Immunomodulatory impressions of MSCs in the injured tissue	28623
Immunomodulatory impressions	28623
MSCs in the injured tissue	28655
MSCs	28655
the injured tissue	28663
one of the reasons why neurons and axons can survive after transplantation -LRB- Caplan , 2007 -RRB-	28689
one	28689
the reasons why neurons and axons can survive after transplantation -LRB- Caplan , 2007 -RRB-	28696
the reasons	28696
neurons and axons	28712
transplantation	28748
Caplan	28765
2007	28773
Injection of OEC	28780
Injection	28780
OEC	28793
significant improvement	28804
the BBB score compared to control group	28831
the BBB score	28831
group	28865
addition	28875
axon density in OEC group	28885
axon density	28885
OEC group	28901
control group	28942
Previous studies	28957
OECs	28986
several neurotrophic factors such as stromal cell derived factor 1-alpha -LRB- SDF-1-alfa -RRB- and BDNF which can provide trophic support for injured neurons , angiogenesis , axonal remyelination and enhancement of axonal regeneration -LRB- Chiu et al. , 2009 ; Kocsis et al. , 2009 -RRB-	29000
several neurotrophic factors	29000
stromal cell derived factor 1-alpha -LRB- SDF-1-alfa -RRB- and BDNF which can provide trophic support for injured neurons , angiogenesis , axonal remyelination and enhancement of axonal regeneration -LRB- Chiu et al. , 2009 ; Kocsis et al. , 2009 -RRB-	29037
stromal cell	29037
factor 1-alpha -LRB- SDF-1-alfa -RRB- and BDNF which can provide trophic support for injured neurons , angiogenesis , axonal remyelination and enhancement of axonal regeneration -LRB- Chiu et al. , 2009 ; Kocsis et al. , 2009 -RRB-	29058
factor 1-alpha -LRB- SDF-1-alfa -RRB-	29058
factor 1-alpha	29058
SDF-1-alfa	29074
BDNF which can provide trophic support for injured neurons , angiogenesis , axonal remyelination and enhancement of axonal regeneration -LRB- Chiu et al. , 2009 ; Kocsis et al. , 2009 -RRB-	29090
BDNF	29090
trophic support for injured neurons , angiogenesis , axonal remyelination and enhancement of axonal regeneration	29113
trophic support	29113
injured neurons , angiogenesis , axonal remyelination and enhancement	29133
axonal regeneration	29204
Chiu	29225
et al. , 2009 ; Kocsis et al. , 2009	29230
et al.	29230
2009 ; Kocsis et al.	29238
2009	29238
Kocsis et al.	29244
Kocsis	29244
et al.	29251
2009	29259
some studies	29275
injection of OEC	29303
injection	29303
OEC	29316
spinal repair in animal model -LRB- Takami et al. , 2002 -RRB-	29344
spinal repair	29344
animal model -LRB- Takami et al. , 2002 -RRB-	29361
animal model	29361
Takami	29375
et al. , 2002	29382
et al.	29382
2002	29390
most of them	29397
most	29397
them	29405
these cells	29422
a good choice for spinal regeneration -LRB- López Vales et al. , 2007 ; Verdú et al. , 2003 -RRB-	29438
a good choice	29438
spinal regeneration -LRB- López Vales et al. , 2007 ; Verdú et al. , 2003 -RRB-	29456
spinal regeneration	29456
López Vales	29477
et al. , 2007 ; Verdú et al. , 2003	29489
et al.	29489
2007 ; Verdú et al.	29497
2007	29497
Verdú et al.	29503
Verdú	29503
et al.	29509
2003	29517
The discrepancy in results	29524
The discrepancy	29524
results	29543
many factors including variations in culture protocols	29574
many factors	29574
variations in culture protocols	29597
variations	29597
culture protocols	29611
one recent work Novikova et al.	29633
one recent work	29633
Novikova et al.	29649
Novikova	29649
et al.	29658
OECs	29675
short term -LRB- three weeks -RRB- and long term -LRB- seven weeks -RRB-	29693
short term -LRB- three weeks -RRB-	29693
short term	29693
three weeks	29705
long term -LRB- seven weeks -RRB-	29722
long term	29722
seven weeks	29733
cultures	29755
short term	29780
OEC cultures	29800
regrowth of rubrospinal , raphaespinal and CGRP positive fibers	29827
regrowth	29827
rubrospinal , raphaespinal and CGRP positive fibers	29839
CGRP	29869
significant neuroprotection	29903
axotomized rubrospinal neurons -LRB- Novikova et al. , 2011b -RRB-	29935
axotomized rubrospinal neurons	29935
Novikova	29967
et al. , 2011b	29976
et al.	29976
2011b	29984
our experiment	29995
OECs	30011
25 days	30056
the animals	30105
such short term	30124
cultures	30149
the desired result	30170
our study	30192
further this work	30206
we	30225
simultaneous injection of OECs and NIMSCs	30254
simultaneous injection	30254
OECs and NIMSCs	30280
spinal cord regeneration	30300
there	30335
any synergistic effect between the two types of cells tested in this work , on each own	30344
any synergistic effect	30344
the two types of cells tested in this work , on each own	30375
the two types	30375
cells tested in this work , on each own	30392
cells	30392
this work	30408
each own	30422
regard to different capacities of these cells and different mechanisms through which these cells make their effects	30437
regard	30437
different capacities of these cells and different mechanisms through which these cells make their effects	30447
different capacities of these cells	30447
different capacities	30447
these cells	30471
different mechanisms through which these cells make their effects	30487
different mechanisms	30487
these cells	30522
their effects	30539
most probably harnessing the whole potential of both of these cell types	30554
most	30554
the whole potential of both of these cell types	30579
the whole potential	30579
both of these cell types	30602
both	30602
these cell types	30610
enough value to see if the mentioned cells have merit to be considered as suitable candidates for cell therapy approaches of spinal cord injuries	30631
the mentioned cells	30654
suitable candidates for cell therapy approaches of spinal cord injuries	30705
suitable candidates	30705
cell therapy approaches of spinal cord injuries	30729
cell therapy approaches	30729
spinal cord injuries	30756
